141 related articles for article (PubMed ID: 16476059)
1. CTLA-4 interacts with STAT5 and inhibits STAT5-mediated transcription.
Srahna M; Van Grunsven LA; Remacle JE; Vandenberghe P
Immunology; 2006 Mar; 117(3):396-401. PubMed ID: 16476059
[TBL] [Abstract][Full Text] [Related]
2. TCR subunit specificity of CTLA-4-mediated signaling.
Siu E; Carreno BM; Madrenas J
J Leukoc Biol; 2003 Dec; 74(6):1102-7. PubMed ID: 12972512
[TBL] [Abstract][Full Text] [Related]
3. Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression.
Chuang E; Alegre ML; Duckett CS; Noel PJ; Vander Heiden MG; Thompson CB
J Immunol; 1997 Jul; 159(1):144-51. PubMed ID: 9200449
[TBL] [Abstract][Full Text] [Related]
4. IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT.
Tsuji-Takayama K; Suzuki M; Yamamoto M; Harashima A; Okochi A; Otani T; Inoue T; Sugimoto A; Motoda R; Yamasaki F; Nakamura S; Kibata M
Exp Hematol; 2008 Feb; 36(2):181-92. PubMed ID: 18023521
[TBL] [Abstract][Full Text] [Related]
5. Regulation of CD28 expression on CD8+ T cells by CTLA-4.
Berg M; Zavazava N
J Leukoc Biol; 2008 Apr; 83(4):853-63. PubMed ID: 18162511
[TBL] [Abstract][Full Text] [Related]
6. Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28null T cells.
Hoff H; Knieke K; Cabail Z; Hirseland H; Vratsanos G; Burmester GR; Jorch G; Nadler SG; Bröker B; Hebel K; Brunner-Weinzierl MC
J Immunol; 2009 May; 182(9):5342-51. PubMed ID: 19380781
[TBL] [Abstract][Full Text] [Related]
7. Refolding and characterization of recombinant human soluble CTLA-4 expressed in Escherichia coli.
Cox GN; Pratt D; Smith D; McDermott MJ; Vanderslice RW
Protein Expr Purif; 1999 Oct; 17(1):26-32. PubMed ID: 10497065
[TBL] [Abstract][Full Text] [Related]
8. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
9. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation.
Saverino D; Brizzolara R; Simone R; Chiappori A; Milintenda-Floriani F; Pesce G; Bagnasco M
Clin Immunol; 2007 May; 123(2):190-8. PubMed ID: 17321799
[TBL] [Abstract][Full Text] [Related]
10. Involvement of CTLA-4 in T-cell anergy induced by staphylococcal enterotoxin A in vitro.
Xu GL; Zhu XH; Guo B; Wu YZ
Mol Immunol; 2004 May; 41(1):1-8. PubMed ID: 15140570
[TBL] [Abstract][Full Text] [Related]
11. Physical and functional interactions between STAT5 and Runx transcription factors.
Ogawa S; Satake M; Ikuta K
J Biochem; 2008 May; 143(5):695-709. PubMed ID: 18296717
[TBL] [Abstract][Full Text] [Related]
12. Modulation of cell cycle progression by CTLA4-CD80/CD86 interactions on CD4+ T cells depends on strength of the CD3 signal: critical role for IL-2.
Mukherjee S; Ahmed A; Malu S; Nandi D
J Leukoc Biol; 2006 Jul; 80(1):66-74. PubMed ID: 16624934
[TBL] [Abstract][Full Text] [Related]
13. Selective expansion of genetically modified T cells using an antibody/interleukin-2 receptor chimera.
Sogo T; Kawahara M; Tsumoto K; Kumagai I; Ueda H; Nagamune T
J Immunol Methods; 2008 Aug; 337(1):16-23. PubMed ID: 18589435
[TBL] [Abstract][Full Text] [Related]
14. Reversal of the TCR stop signal by CTLA-4.
Schneider H; Downey J; Smith A; Zinselmeyer BH; Rush C; Brewer JM; Wei B; Hogg N; Garside P; Rudd CE
Science; 2006 Sep; 313(5795):1972-5. PubMed ID: 16931720
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes.
Love VA; Grabie N; Duramad P; Stavrakis G; Sharpe A; Lichtman A
Circ Res; 2007 Aug; 101(3):248-57. PubMed ID: 17569889
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional activation of mouse TCR Jgamma4 germline promoter by STAT5.
Masui N; Tani-ichi S; Maki K; Ikuta K
Mol Immunol; 2008 Feb; 45(3):849-55. PubMed ID: 17664008
[TBL] [Abstract][Full Text] [Related]
17. CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice.
Kolar P; Knieke K; Hegel JK; Quandt D; Burmester GR; Hoff H; Brunner-Weinzierl MC
Arthritis Rheum; 2009 Jan; 60(1):123-32. PubMed ID: 19116935
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of T cell proliferation by cholera toxin involves the modulation of costimulatory molecules CTLA-4 and CD28.
Vendetti S; Riccomi A; Sacchi A; Sciaraffia E; Gatta L; Pioli C; De Magistris MT
Immunol Lett; 2008 Jan; 115(1):59-69. PubMed ID: 18031829
[TBL] [Abstract][Full Text] [Related]
19. Human Soluble CD80 is generated by alternative splicing, and recombinant soluble CD80 binds to CD28 and CD152 influencing T-cell activation.
Kakoulidou M; Giscombe R; Zhao X; Lefvert AK; Wang X
Scand J Immunol; 2007 Nov; 66(5):529-37. PubMed ID: 17953528
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo effects of zinc on cytokine signalling in human T cells.
Varin A; Larbi A; Dedoussis GV; Kanoni S; Jajte J; Rink L; Monti D; Malavolta M; Marcellini F; Mocchegiani E; Herbein G; Fulop T
Exp Gerontol; 2008 May; 43(5):472-82. PubMed ID: 18249079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
